UNSPSC 51171639: Oxyphenisatin or oxyphenisatine

This classification denotes a laxative with the molecular formula C20H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3BT0VQG2GQ, chemically known as 4,4-dihydroxydiphenylisatin but generally known as oxyphenisatin, which bears US NIH Compound Identifier 31315. European Medicines Agency schedules Oxyphenisatine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09574MIG.

The term OXYPHENISATINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). World Health Organization schedules oxyphenisatin in its Anatomical Therapeutic Chemical (ATC) Classification. Oxyphenisatin or oxyphenisatine bears US NLM identifiers UMLS ID C0031422 and NCI Concept Code C80953. SMILES: C1=CC=C2C(=C1)C(C(=O)N2)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O.

UNSPSC 51171639 Oxyphenisatin or oxyphenisatine, a Commodity code, shows minimal recent state and local procurement activity directly aligned with the chemical substance itself. The three most recent state and local opportunities tagged under this code involve offender drug testing services, pharmaceutical benefit program strategy, and generic multi-source pharmaceuticals distribution — none of which target oxyphenisatin as a primary procurement object or chemical reagent input. The code appears to reflect a taxonomy mismatch rather than active demand for this specific compound in state and local purchasing.

The one opportunity with concrete scope and timeline is Collin County Community Supervision and Corrections Department's RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026. That procurement centers on staffing collection sites, operating an Interactive Voice Response system, conducting immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), and alternative testing methodologies — work that may incidentally involve chemical reagents but does not specifically solicit oxyphenisatin. The Texas Health and Human Services Commission's RFI on Direct-to-Manufacturer Prescriptions and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for Generic Multi-Source Pharmaceuticals and OTC Products (responses due March 26, 2026) address pharmaceutical procurement broadly, but neither identifies oxyphenisatin as a targeted substance. Business development professionals should verify whether oxyphenisatin has a more appropriate UNSPSC classification or whether state and local demand for this particular compound exists outside these tagged solicitations.